Afatinib
- Generic Name
- Afatinib
- Brand Names
- Gilotrif, Giotrif
- Drug Type
- Small Molecule
- Chemical Formula
- C24H25ClFN5O3
- CAS Number
- 850140-72-6
- Unique Ingredient Identifier
- 41UD74L59M
- Background
Afatinib is a 4-anilinoquinazoline tyrosine kinase inhibitor in the form of a dimaleate salt available as Boehringer Ingelheim's brand name Gilotrif . For oral use, afatinib tablets are a first-line (initial) treatment for patients with metastatic non-small cell lung cancer (NSCLC) with common epidermal growth factor receptor (EGFR) mutations as detected by ...
- Indication
Afatinib is a kinase inhibitor indicated as monotherapy for the first-line treatment of (a) Epidermal Growth Factor Receptor (EGFR) TKI (tyrosine kinase inhibitor)-naive adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumours have non-resistant EGFR mutations as detected by an FDA-approved test , and (b) adult pa...
- Associated Conditions
- Metastatic Non-Small Cell Lung Cancer, Refractory, metastatic squamous cell Non-small cell lung cancer
- Associated Therapies
- -
Clinical Study for the Treatment of Breast Cancer: the Patient Will Receive Afatinib Plus Letrozole or Letrozole Alone
- First Posted Date
- 2014-04-15
- Last Posted Date
- 2019-12-26
- Lead Sponsor
- Translational Research in Oncology
- Target Recruit Count
- 44
- Registration Number
- NCT02115048
- Locations
- 🇧🇦
University Hospital Clinical Center Banja Luka, Oncology Clinic, Banja Luka, Bosnia and Herzegovina
🇺🇸DBA Torrance Memorial Physician Network/Cancer Care Associates, Redondo Beach, California, United States
🇪🇸Hospital Clínico Universitario Virgen de La Arrixaca, Murcia, Spain
GIOTRIF in First Line Therapy of Advanced NSCLC With EGFR-mutations
- First Posted Date
- 2014-01-28
- Last Posted Date
- 2020-01-09
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 161
- Registration Number
- NCT02047903
Afatinib in Patients With Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Mutations
- First Posted Date
- 2014-01-24
- Last Posted Date
- 2017-03-31
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 14
- Registration Number
- NCT02044380
- Locations
- 🇨🇦
Boehringer Ingelheim Investigational Site, Montreal, Quebec, Canada
Trial of Afatinib (BIBW 2992) + Cetuximab in Advanced Solid Tumours
- First Posted Date
- 2013-12-25
- Last Posted Date
- 2017-06-22
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 58
- Registration Number
- NCT02020577
- Locations
- 🇫🇷
1200.122.33001 Boehringer Ingelheim Investigational Site, Villejuif Cedex, France
🇪🇸1200.122.34001 Boehringer Ingelheim Investigational Site, Madrid, Spain
Afatinib (BIBW 2992) in Advanced Non-Small Cell Lung Cancer Patients With EGFR Mutation
- First Posted Date
- 2013-10-01
- Last Posted Date
- 2019-08-12
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 542
- Registration Number
- NCT01953913
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, China
🇨🇳Shanghai Chest Hospital, Shanghai, China
🇨🇳Shanghai Pulmonary Hospital, Shanghai, China
Expanded Access Study of Afatinib in Treatment-naive or Chemotherapy Pre-treated Patients With Non-small Cell Lung Cancer (NSCLC)
- Conditions
- First Posted Date
- 2013-08-29
- Last Posted Date
- 2018-11-14
- Lead Sponsor
- Boehringer Ingelheim
- Registration Number
- NCT01931306
- Locations
- 🇰🇷
The Catholic University of Korea, Bucheon St.Mary's Hospital, Bucheon, Korea, Republic of
🇰🇷Chonnam National University Hwasun Hospital, Jeonnam, Korea, Republic of
🇰🇷Gachon University Gil Medical Center, Incheon, Korea, Republic of
LUX-Head&Neck 3: Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2013-05-17
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 340
- Registration Number
- NCT01856478
- Locations
- 🇨🇳
Harbin Medical University Cancer Hospital, Harbin, China
🇨🇳Beijing Chao-Yang Hospital, Beijing, China
🇨🇳Cancer Hospital of Chinese Academy of Medical Science, Beijing, China
An Open Label Trial of Afatinib (Giotrif) in Treatment-naive (1st Line) or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s)
- First Posted Date
- 2013-05-15
- Last Posted Date
- 2024-03-26
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 481
- Registration Number
- NCT01853826
- Locations
- 🇮🇹
A.O. Univ. Policlinico "Paolo Giaccone", Palermo, Italy
🇨🇿University Hospital Ostrava, Ostrava, Czechia
🇮🇱Rabin Medical Center Beilinson, Petah Tikva, Israel
Afatinib In Combination With Cisplatin Or Carboplatin + Pemetrexed In Patients With EGFR-Mutant Lung Cancers Undergoing Definitive Chemoradiation
- Conditions
- Interventions
- First Posted Date
- 2013-04-19
- Last Posted Date
- 2013-12-19
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT01836341
Afatinib After Chemoradiation and Surgery in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck at High-Risk of Recurrence
- Conditions
- Interventions
- First Posted Date
- 2013-04-05
- Last Posted Date
- 2023-06-28
- Lead Sponsor
- ECOG-ACRIN Cancer Research Group
- Target Recruit Count
- 3
- Registration Number
- NCT01824823
- Locations
- 🇺🇸
John H Stroger Jr Hospital of Cook County, Chicago, Illinois, United States
🇺🇸University of Illinois, Chicago, Illinois, United States
🇺🇸Bozeman Deaconess Hospital, Bozeman, Montana, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.